Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Andreas Liebl

15 Years of Experience With Biphasic Insulin Aspart 30 in Type 2 Diabetes

Drugs in R and D

Pharmacology

2018

English

Related publications

Use of Biphasic Insulin Aspart 30 in Type 2 Diabetes Treatment: Expert Panel Recommendations

Turkish Journal of Endocrinology and Metabolism

English

Comparison of a Soluble Co-Formulation of Insulin Degludec/Insulin Aspart vs Biphasic Insulin Aspart 30 in Type 2 Diabetes: A Randomised Trial

European Journal of Endocrinology

English

Efficacy and Safety of Three-Times-Daily Versus Twice-Daily Biphasic Insulin Aspart 30 in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Combined With Oral Antidiabetic Drugs

Diabetes Research and Clinical Practice

English

Safety and Effectiveness of Biphasic Insulin Aspart 30/70 (NovoMix®30) When Switching From Human Premix Insulin in Patients With Type 2 Diabetes: Subgroup Analysis From the 6-Month IMPROVE™ Observational Study

International Journal of Clinical Practice

Medicine

2009

English

Budget Impact Analysis of Biphasic Insulin Aspart in the Treatment of Type 2 Diabetes Mellitus in Malaysia: A Public Payer Perspective

English

A Survey of Physician Experience and Treatment Satisfaction Using Fast-Acting Insulin Aspart in People With Type 1 or Type 2 Diabetes

Postgraduate Medicine

Medicine

2020

English

Biphasic Insulin Aspart 30 Therapy in Insulin-Naïve and Insulin-Experienced Patients With Type 2 Diabetes: Results From the Jordanian Subgroup of the A<sub>1</Sub>chieve Study

Journal of Diabetes Mellitus

2014

English

Safety and Effectiveness of Biphasic Insulin Aspart 30 in Different Age-Groups: A1chieve Sub-Analysis

English

Initiation of Biphasic Insulin Aspart in a Patient Failing Basal Insulin Treatment

European Endocrinology

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Andreas Liebl

15 Years of Experience With Biphasic Insulin Aspart 30 in Type 2 Diabetes

Related publications

Use of Biphasic Insulin Aspart 30 in Type 2 Diabetes Treatment: Expert Panel Recommendations

Comparison of a Soluble Co-Formulation of Insulin Degludec/Insulin Aspart vs Biphasic Insulin Aspart 30 in Type 2 Diabetes: A Randomised Trial

Efficacy and Safety of Three-Times-Daily Versus Twice-Daily Biphasic Insulin Aspart 30 in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Combined With Oral Antidiabetic Drugs

Safety and Effectiveness of Biphasic Insulin Aspart 30/70 (NovoMix®30) When Switching From Human Premix Insulin in Patients With Type 2 Diabetes: Subgroup Analysis From the 6-Month IMPROVE™ Observational Study

Budget Impact Analysis of Biphasic Insulin Aspart in the Treatment of Type 2 Diabetes Mellitus in Malaysia: A Public Payer Perspective

A Survey of Physician Experience and Treatment Satisfaction Using Fast-Acting Insulin Aspart in People With Type 1 or Type 2 Diabetes

Biphasic Insulin Aspart 30 Therapy in Insulin-Na&#239;ve and Insulin-Experienced Patients With Type 2 Diabetes: Results From the Jordanian Subgroup of the A&lt;sub&gt;1&lt;/Sub&gt;chieve Study

Safety and Effectiveness of Biphasic Insulin Aspart 30 in Different Age-Groups: A1chieve Sub-Analysis

Initiation of Biphasic Insulin Aspart in a Patient Failing Basal Insulin Treatment

Biphasic Insulin Aspart 30 Therapy in Insulin-Naïve and Insulin-Experienced Patients With Type 2 Diabetes: Results From the Jordanian Subgroup of the A<sub>1</Sub>chieve Study